PLUS THERAPEUTICS, Inc. Common Stock
PSTVPlus Therapeutics, Inc. (PSTV) is a clinical-stage biopharmaceutical company focused on developing targeted radiopharmaceuticals for the treatment of cancer. The company aims to leverage novel radioisotope-based therapies to improve outcomes for patients with difficult-to-treat tumors, utilizing advanced delivery platforms to enhance efficacy and minimize side effects.
Company News
Plus Therapeutics announced 2026 milestones focused on CNSide commercial scale-up and REYOBIQ pivotal trial readiness, backed by a recently completed $15 million offering. The company aims to achieve 150 million US lives covered under commercial payor agreements, obtain Medicare/Medicaid coverage, and report Phase 2 trial data for REYOBIQ in trea...
CNSide Diagnostics, a subsidiary of Plus Therapeutics, secured a national agreement with UnitedHealthcare covering over 51 million people for its cerebrospinal fluid tumor cell diagnostic test, which has demonstrated high sensitivity and specificity in cancer diagnosis.
The leptomeningeal metastases market is projected to grow slowly due to rising cancer incidence and increasing central nervous system complications. Several emerging therapies like REYOBIQ and Paxalisib are expected to drive market development in the coming years.
Arch Therapeutics is developing innovative self-assembling barrier technologies for interventional wound care, focusing on advanced hemostasis and sealant solutions across multiple medical applications.
Plus Therapeutics, a clinical-stage pharmaceutical company, announced the pricing of a $15.0 million private placement. The funds will be used to advance the company's central nervous system cancer therapies and meet key near-term milestones.
